178 related articles for article (PubMed ID: 12824882)
1. Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells.
Mukai M; Che XF; Furukawa T; Sumizawa T; Aoki S; Ren XQ; Haraguchi M; Sugimoto Y; Kobayashi M; Takamatsu H; Akiyama S
Cancer Sci; 2003 Jun; 94(6):557-63. PubMed ID: 12824882
[TBL] [Abstract][Full Text] [Related]
2. Reversal of P-glycoprotein mediated multidrug resistance by a newly synthesized 1,4-benzothiazipine derivative, JTV-519.
Che XF; Nakajima Y; Sumizawa T; Ikeda R; Ren XQ; Zheng CL; Mukai M; Furukawa T; Haraguchi M; Gao H; Sugimoto Y; Akiyama S
Cancer Lett; 2002 Dec; 187(1-2):111-9. PubMed ID: 12359358
[TBL] [Abstract][Full Text] [Related]
3. Anti-proliferative effect of the abl tyrosine kinase inhibitor STI571 on the P-glycoprotein positive K562/ADM cell line.
Kotaki M; Motoji T; Takanashi M; Wang YH; Mizoguchi H
Cancer Lett; 2003 Sep; 199(1):61-8. PubMed ID: 12963124
[TBL] [Abstract][Full Text] [Related]
4. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.
Donato NJ; Wu JY; Stapley J; Gallick G; Lin H; Arlinghaus R; Talpaz M
Blood; 2003 Jan; 101(2):690-8. PubMed ID: 12509383
[TBL] [Abstract][Full Text] [Related]
5. Timosaponin A-III reverses multi-drug resistance in human chronic myelogenous leukemia K562/ADM cells via downregulation of MDR1 and MRP1 expression by inhibiting PI3K/Akt signaling pathway.
Chen JR; Jia XH; Wang H; Yi YJ; Wang JY; Li YJ
Int J Oncol; 2016 May; 48(5):2063-70. PubMed ID: 26984633
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways.
Tang C; Schafranek L; Watkins DB; Parker WT; Moore S; Prime JA; White DL; Hughes TP
Leuk Lymphoma; 2011 Nov; 52(11):2139-47. PubMed ID: 21718141
[TBL] [Abstract][Full Text] [Related]
7. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells.
Topaly J; Zeller WJ; Fruehauf S
Leukemia; 2001 Mar; 15(3):342-7. PubMed ID: 11237055
[TBL] [Abstract][Full Text] [Related]
8. STI571 combined with vincristine greatly suppressed the tumor formation of multidrug-resistant K562 cells in a human-nude mice xenograft model.
Gao L; Chen L; Fei XH; Qiu HY; Zhou H; Wang JM
Chin Med J (Engl); 2006 Jun; 119(11):911-8. PubMed ID: 16780770
[TBL] [Abstract][Full Text] [Related]
9. Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro.
Mow BM; Chandra J; Svingen PA; Hallgren CG; Weisberg E; Kottke TJ; Narayanan VL; Litzow MR; Griffin JD; Sausville EA; Tefferi A; Kaufmann SH
Blood; 2002 Jan; 99(2):664-71. PubMed ID: 11781252
[TBL] [Abstract][Full Text] [Related]
10. Germacrone reverses adriamycin resistance in human chronic myelogenous leukemia K562/ADM cells by suppressing MDR1 gene/P-glycoprotein expression.
Pan J; Miao D; Chen L
Chem Biol Interact; 2018 May; 288():32-37. PubMed ID: 29655913
[TBL] [Abstract][Full Text] [Related]
11. Targeting P-Glycoprotein: Nelfinavir Reverses Adriamycin Resistance in K562/ADR Cells.
Liu W; Meng Q; Sun Y; Wang C; Huo X; Liu Z; Sun P; Sun H; Ma X; Liu K
Cell Physiol Biochem; 2018; 51(4):1616-1631. PubMed ID: 30497065
[TBL] [Abstract][Full Text] [Related]
12. Aminopeptidase inhibitors inhibit proliferation and induce apoptosis of K562 and STI571-resistant K562 cell lines through the MAPK and GSK-3beta pathways.
Sawafuji K; Miyakawa Y; Weisberg E; Griffin JD; Ikeda Y; Kizaki M
Leuk Lymphoma; 2003 Nov; 44(11):1987-96. PubMed ID: 14738154
[TBL] [Abstract][Full Text] [Related]
13. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571.
Gambacorti-Passerini C; Barni R; le Coutre P; Zucchetti M; Cabrita G; Cleris L; Rossi F; Gianazza E; Brueggen J; Cozens R; Pioltelli P; Pogliani E; Corneo G; Formelli F; D'Incalci M
J Natl Cancer Inst; 2000 Oct; 92(20):1641-50. PubMed ID: 11036109
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.
Koyama N; Koschmieder S; Tyagi S; Portero-Robles I; Chromic J; Myloch S; Nürnberger H; Rossmanith T; Hofmann WK; Hoelzer D; Ottmann OG
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2025-31. PubMed ID: 16609011
[TBL] [Abstract][Full Text] [Related]
15. [Synergistic inhibitory effect of STI571 in combination with arsenic trioxide on a multidrug-resistant leukemia cell line expressing bcr-abl].
Chen L; Wang JM; Xu XP; Gao L; Fei XH; Lou JW; Huang ZX
Zhonghua Zhong Liu Za Zhi; 2004 Sep; 26(9):535-8. PubMed ID: 15555283
[TBL] [Abstract][Full Text] [Related]
16. Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair.
Majsterek I; Sliwinski T; Poplawski T; Pytel D; Kowalski M; Slupianek A; Skorski T; Blasiak J
Mutat Res; 2006 Jan; 603(1):74-82. PubMed ID: 16388976
[TBL] [Abstract][Full Text] [Related]
17. Distinct interaction of nilotinib and imatinib with P-Glycoprotein in intracellular accumulation and cytotoxicity in CML Cell Line K562 cells.
Yamakawa Y; Hamada A; Uchida T; Sato D; Yuki M; Hayashi M; Kawaguchi T; Saito H
Biol Pharm Bull; 2014; 37(8):1330-5. PubMed ID: 25087954
[TBL] [Abstract][Full Text] [Related]
18. INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity.
Yokota A; Kimura S; Masuda S; Ashihara E; Kuroda J; Sato K; Kamitsuji Y; Kawata E; Deguchi Y; Urasaki Y; Terui Y; Ruthardt M; Ueda T; Hatake K; Inui K; Maekawa T
Blood; 2007 Jan; 109(1):306-14. PubMed ID: 16954504
[TBL] [Abstract][Full Text] [Related]
19. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents.
Kano Y; Akutsu M; Tsunoda S; Mano H; Sato Y; Honma Y; Furukawa Y
Blood; 2001 Apr; 97(7):1999-2007. PubMed ID: 11264164
[TBL] [Abstract][Full Text] [Related]
20. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L).
Perkins C; Kim CN; Fang G; Bhalla KN
Blood; 2000 Feb; 95(3):1014-22. PubMed ID: 10648417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
